AEVIS VICTORIA SA - Infracore strengthens its balance sheet and prepares for accelerated growth in 2025

AEVIS VICTORIA SA / Key word(s): Annual Results AEVIS VICTORIA SA - Infracore strengthens its balance sheet and prepares for accelerated growth in 2025 31.03.2025 / 07:00 CET/CEST Press release

Fribourg, 31 March 2025

Infracore strengthens its balance sheet and prepares for accelerated growth in 2025

Infracore SA, a leading Swiss healthcare infrastructure company, today reports solid results for the financial year 2024, marked by continued portfolio expansion, strategic deleveraging and a clear roadmap for growth.

2024 Results: Solid performance and strong financial foundations
Infracore posted rental income of CHF 60.5 million, up from CHF 59.6 million in 2023. The company delivered an EBITDA of CHF 59.5 million, representing a robust 90.4% margin. Net profit for the year came in at CHF 33.7 million, slightly lower than the previous year due to an increase in deferred tax expenses. Earnings per share (EPS) amounted to CHF 2.90.

A key highlight was the full repayment of a CHF 100 million bond, significantly reducing the Loan-to-Value (LTV) ratio from 48.0% to 43.3%. The Net Asset Value (NAV) after taxes increased to CHF 600 million, up 6% year-on-year.

A unique track record in hospital infrastructure
Since 2006, Infracore has built up unmatched expertise in the construction, renovation and modernization of hospital sites across Switzerland. With more than 35 projects completed, Infracore is today the country’s leading hospital real estate specialist.

Until now, the company has focused primarily on Swiss Medical Network assets. Moving forward, it intends to offer its know-how to other Swiss healthcare providers, public or private, leveraging its operational, financial and regulatory experience to support their infrastructure transformation.

Genolier Innovation Hub and portfolio expansion
The company’s investment property portfolio increased by CHF 28 million and nearly reached the CHF 1.33 billion mark in 2024, driven by the completion of the Genolier Innovation Hub, a pioneering facility dedicated to medical innovation, training and research. Major investments were also made across the Bethanien, Valmont and Ars Medica sites, contributing to the value growth of the portfolio.